Ignite Creation Date:
2024-05-06 @ 12:53 AM
Last Modification Date:
2024-10-26 @ 10:56 AM
Study NCT ID:
NCT01689519
Status:
COMPLETED
Last Update Posted:
2022-05-02
First Post:
2012-09-18
Brief Title:
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Malignant Melanoma |
Keywords:
| Name | View |
|---|---|
| Zelboraf | View |
| vemurafenib | View |
| RG7204 | View |
| PLX4032 | View |
| Genentech MEK inhibitor | View |
| Genentech BRAF inhibitor | View |
| Roche MEK inhibitor | View |
| Roche BRAF inhibitor | View |
| RO5185426 | View |
| metastatic melanoma | View |
| BRAF positive melanoma | View |
| BRAF mutant melanoma | View |
| advanced melanoma | View |
| Genentech RAF inhibitor | View |
| Roche RAF inhibitor | View |
| BRAF V600E kinase inhibitor | View |
| Oncogenic BRAF inhibitor | View |
| BRAF kinase inhibitor | View |
| GDC-0973 | View |
| XL518 | View |
| melanoma | View |